Amgen hit by T-VEC's Phase III survival miss
This article was originally published in Scrip
Amgen's talimogene laherparepvec (T-VEC) missed the secondary endpoint of overall survival in a Phase III melanoma clinical trial despite the oncolytic immunotherapy's previously reported success in the primary endpoint of durable response rate.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.